#BMS #Cobenfy #schizophrenia #psychiatry Biotech Executive, Thought Leader & Creator | Diagnostics Executive | Microfluidics & Immunoassay Innovation | FDA Strategy Led EUA 230055, EUA 240006 & 510(k) K240728 | Oncology, AIBiology & IVD Commercialization Market Watch | Bristol Myers Squibbs Cobenfy Faces Uptake Challenges Amid Strong Q3 Earnings Bristol Myers Squibb ($BMY) reported $12.2B in Q3 revenue, surpassing analyst expectations yet investor attention centered on Cobenfy, the first new schizophrenia drug in 35 years, which posted $43M in sales, slightly below forecasts
But critically, it does so in a regulated wayit doesnt stimulate abnormal or excessive cell growth the way cancerous processes do
For non-diabetic users the question is whether both are needed: tirzepatide is far stronger for weight loss at 5 mg and above, while metformin is cheaper, oral, and more modest
While these effects may be beneficial in selected cardiovascular indications, they raised concerns regarding hypotension and hemodynamic instability when considered for chronic metabolic disease
The pain and discomfort of a gout attack are distinctive, and understanding these signs is crucial for individuals to seek appropriate treatment and management strategies
That is how medicine is supposed to work and it is how we do it every single time
